Evidence map›Paper›PMID 41482360›Full record

ArticleIn vivo (Athens, Greece)

Lenvatinib Suppresses Colorectal Cancer Cell Growth, Migration, and Invasion

Ching-Hsuan Wu, Fei-Ting Hsu, Chun-Hsien Chen, Pei-En Wang, Huai-Yi Huang, Ling-Ling Hsieh, Cheng-Hsien Chen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ching-Hsuan WuDivision of Hematology and Oncology, Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan, R.O.C.
Fei-Ting HsuDepartment of Life Sciences, National Central University, Taoyuan, Taiwan, R.O.C.
Chun-Hsien ChenDepartment of Life Sciences, National Central University, Taoyuan, Taiwan, R.O.C.
Pei-En WangDepartment of Life Sciences, National Central University, Taoyuan, Taiwan, R.O.C.
Huai-Yi HuangDivision of Gastroenterology and Hepatology, Chang Bing Show Chwan Memorial Hospital, Changhua, Taiwan, R.O.C.
Ling-Ling HsiehDepartment of Medical Imaging and Radiological Sciences, Central Taiwan University of Science and Technology, Taichung, Taiwan, R.O.C.; llhsieh2013@gmail.com.
Cheng-Hsien ChenSurgical Intensive Care Unit, Department of Surgery, Changhua Show Chwan Memorial Hospital, Changhua, Taiwan, R.O.C. picorna@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimColorectal cancer (CRC) remains a major cause of cancer mortality. Lenvatinib, a multi-kinase inhibitor, has emerging anticancer potential, but its effects in CRC are not fully defined. The aim of this study was to identify potential treatment mechanism and efficacy of Lenvatinib on CRC MATERIALS AND MATERIALS: Human CRC cell lines HT-29 and HCT-116 were treated with lenvatinib. Cell viability (MTT assay), proliferation (colony formation), apoptosis (flow cytometry), migration, and invasion (Transwell assay) were assessed. Key signaling pathways were analyzed by western blot.

resultsLenvatinib reduced viability in a dose- and time-dependent manner (IC

conclusionLenvatinib inhibits CRC cell growth, migration, and invasion by inducing dual-pathway apoptosis and inactivating the ERK/STAT3/NF-κB signaling axis, supporting its potential as a therapeutic strategy for colorectal cancer.

Indexed as

ApoptosisColorectal NeoplasmsNF-kappa BPhenylurea CompoundsQuinolinesSignal TransductionSTAT3 Transcription FactorAntineoplastic AgentsCell Line, TumorCell MovementCell ProliferationCell SurvivalHCT116 CellsHumansMAP Kinase Signaling SystemNeoplasm InvasivenessAntineoplastic AgentslenvatinibNF-kappa BPhenylurea CompoundsQuinolinesSTAT3 protein, humanSTAT3 Transcription FactorapoptosisColorectal cancerERK/STAT3/NF-κBlenvatinibproliferation

Identifiers

PMID41482360
PMCPMC12764217

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.